Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Vericel Corporation
VCEL | US
34.37
USD0.70
2.08%
VCEL | US
About Vericel Corporation
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
22/04/2026
Close
34.37
Open
33.92
High
34.39
Low
33.46
Vericel Corporation a commercial-stage biopharmaceutical company engages in the research development manufacture and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic and single or multiple full-thickness cartilage defects of the knee; and Epicel a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge Massachusetts.
View LessVCEL | US
Risk
54.2
Sharpe
-0.43
Luna's Score
43/100
Recommendation
Sell
Luna says (VCEL | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
51.9%1 month
54.2%3 months
44.2%6 months
44.9%Returns
Fundamental Ratios
PE
4.17K
Fwd. PE
66.67
Price to book
8.21
Debt to equity
0.39
Debt to assets
0.25
Ent. to EBITDA
275.26
Ent. to rev.
9.26
PEG
-
Other Fundamentals
EBITDA
1.18M
MarketCap
1.69B
MarketCap(USD)
1.69B
Div. yield
-
Op. margin
-11.45
Erngs. growth
104.50
Rev. growth
14.70
Ret. on equity
0.36
Short ratio
9.26
Short perc.
11.52
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
3.01
Range1M
7.05
Range3M
10.53
Volumes: Market Activity
Rel. volume
0.67
Price X volume
15.42M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 275.26 | - | Expensive |
| Ent. to Revenue | 9.26 | - | Cheaper |
| PE Ratio | 4,166.00 | 41.03 | Expensive |
| Price to Book | 8.21 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 44.23 | - | Lower Risk |
| Debt to Equity | 0.39 | -1.23 | Expensive |
| Debt to Assets | 0.25 | 0.25 | Par |
| Market Cap | 1.69B | - | Emerging |
